# **STOPAN**

Pain relief/antispasmodic medicine for the stomach

ullet STOPAN is a painkilling anti-inflammatory gastrointestinal medicine that alleviates acute stomachache/ abdominal pain due to stress.  $\Box$ 

◆Tiquizium bromide blocks M 3 receptor in the gastrointestinal smooth muscle, alleviates abnormal contraction in sensitive stomach and bowel, and relieves painful symptoms. ■Small capsules are easy to swallow. One capsule one time takes effect. ★M 3 receptor refers to muscarinic 3 receptor involved in gastrointestinal contraction.

#### Indication

Stomachache, abdominal pain, abdominal cramps

(The drug contains an ingredient to alleviate gastrointestinal tensions.)

### Dosage and administration

Take the following dose with cold or lukewarm water.

Take at least 5 hours between doses.

15 years or over: 1 capsule per dose, up to 3 times daily

Under 15 years: Do not take

Comply with the prescribed dosage and administration instructions.

If severe pain is not relieved in a few hours after taking the drug\* or if symptoms do not resolve after using the drug for 5–6 doses, discontinue the use of this drug, and contact a physician, pharmacist, or registered salesperson for a consultation.

·How to take out the capsules

•Press the convex part of the PTP sheet containing the capsule firmly with your fingertips, break the aluminum foil on the back side, and take out the capsule. (If the capsules are inadvertently taken together with the PTP sheet containing them, it will lead to unexpected accidents, such as the sharp edge sticking into the esophageal mucosa.)

It could be other serious diseases [boring (hole in the gastrointestine), strangulation of the hernia (a part of the intestine deviates, and does not return to the normal position, thus resulting in intestinal obstruction), etc.].

# ingredient and amount

In 1 capsule

Tiquizium Bromide 5mg

### Excipients

Lactose ,Corn starch ,Magnesium stearate,Gelatin,Titanium oxide,Sodium lauryl sulfate

#### Precautions

### When not to use the product

(If you do not follow these instructions, the current symptoms may worsen or adverse reactions/incidents are more likely to occur.)

This product should not be used in the following persons:

Patients who have had an allergic symptom to this drug, its ingredients, or other Analgesic Antispasmodics Persons diagnosed as having the following

Symptoms may be exacerbated.

Glaucoma, prostatic hypertrophy, heart disease, paralytic ileus (intestinal obstruction), hyperthyroidism, arrhythmia, and ulcerative colitis

This drug should not be taken together with the following drugs:

Other pain relief/antispasmodic medicine for the stomach, other gastrointestinal medicine containing scopolia extract, medicine for motion sickness

Internal medicine containing antihistamines (cold medicine, expectorant, internal medicine for rhinitis, medicine for allergies,, etc.)

• After taking this drug, do not drive a car or operate machinery (symptoms such as blurred vision and abnormal brightness may occur).

### Consultation

• The following persons should contact a physician, pharmacist, or registered salesperson for a consultation before administration.

Persons undergoing medical treatment from a physician or persons on other oral medications.

Pregnant women or women suspected of being pregnant.

Nursing women.

The elderly

Physically weak person

Patients who have experienced allergic symptoms associated with drugs, etc.

Persons with the following symptoms:

urination difficulty

• If the following symptoms are observed after taking this drug, these may be adverse reactions, so immediately

11-Jul-2019 1/2 page

discontinue the use of this drug, and show this document to your physician, pharmacist, or registered salesperson for a consultation.

Skin

rash/redness

itching

Gastrointestinal system

nausea and vomiting

Loss of appetite

feeling of discomfort in the stomach

feeling of fullness in the abdomen

Heartburn (gastroesophageal reflux)

Neuropsychiatric system

headache

Heavy-headedness

Other:

Facial hot flashes

abnormal brightness

urination difficulty

Frequent urination

palpitations

Ear ringing

The following serious symptoms may occur in rare cases. In such cases, immediately seek medical aid:

Shock (anaphylaxis): Symptoms, such as itching of skin, urticaria, hoarseness, sneezing, itchy throat, breathing difficulties, palpitations, and clouding of consciousness may occur immediately after taking the drug.

Hepatic function failure: Symptoms, such as fever, itching, rash, jaundice (yellowing of skin and white of eyes), brown urine, general malaise, loss of appetite, etc. may occur.

• The following symptoms may be observed after taking this drug. If these symptoms persist or worsen , discontinue the use of this drug, and show this document to your physician, pharmacist, or registered salesperson for a consultation. Diarrhea, constipation, and dry mouth

blurred vision

If severe pains do not subside in a few hours after taking this drug, discontinue the use of this drug, and show ...

# Precautions for storage and handling

Avoid direct sunlight, and store the product in a cool place with little humidity.

Store the product beyond the reach of children.

Do not transfer the drug to other containers. (It may lead to misuse or quality deterioration)

Do not take the product past the expiration date.

[Disclaimer on Multilingual OTC Product Information]

- •This product is a pharmaceutical product approved under a Japanese law, the Law for Ensuring the Quality, Efficacy and Safety of Drugs and Medical Devices, with a view to its sale and use in Japan.
- •Multilingual product information is a translation of the product labeling written in Japanese and provided for your information only. It does not warrant that its contents and the product itself conforms to laws and regulations in countries other than Japan.
- •Multilingual product information is a tentative translation by the provider (or Our Company), and may be modified or altered without notice.
- •The provider (or Our Company) assumes no responsibility for any occurred problem attributable to the contents of the multilingual product information.

43

11-Jul-2019 2/2 page